Mylan Fights FDA On Teva's Provigil Market Rights
Mylan Inc. asked a federal judge Wednesday to block the U.S. Food and Drug Administration's decision giving Teva Pharmaceuticals USA Inc. 180-day exclusivity to market a generic version of Provigil, arguing...To view the full article, register now.
Already a subscriber? Click here to view full article